Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$14.40 – $17.76
82% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $990.0K | $13.8M | $9.2M | $31.0M | $15.6M | $9.2M | $0 | $0 |
| Cost of revenue | $39.0M | $24.9M | $44.8M | $47.1M | $64.3M | $1.0M | $490.0K | $0 |
| Gross profit | −$38.0M | −$11.2M | −$35.7M | −$16.1M | $13.6M | $8.1M | −$490.0K | $0 |
| Gross margin | -3838.0% | -81.3% | -387.8% | -52.0% | 87.0% | 88.9% | — | — |
| R&D | $38.6M | $24.9M | $44.8M | $47.1M | $64.3M | $59.7M | $30.4M | $28.5M |
| Operating income | −$40.9M | −$18.5M | −$44.5M | −$34.1M | −$70.9M | −$75.4M | −$54.6M | −$48.5M |
| EBITDA | −$40.4M | −$18.4M | −$44.2M | −$33.6M | −$70.2M | −$74.4M | −$48.6M | $328.0K |
| Net income | −$40.9M | −$16.8M | −$44.3M | −$34.1M | −$68.8M | −$68.2M | −$49.2M | −$52.4M |
| Net margin | -4127.8% | -122.3% | -481.4% | -110.1% | -440.3% | -744.2% | — | — |
| EPS (diluted) | -1.14 | -0.47 | -3.16 | -0.95 | -1.90 | -1.63 | -1.02 | 0.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-0.75 | $-0.75–$-0.75 | 1 |
| 2027 | $4M | $-1.02 | $-1.02–$-1.02 | 1 |
| 2028 | $19M | $-1.13 | $-1.13–$-1.13 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds IKNA.
No tracked institution reports a position in IKNA as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-07-28 | 1-for-12reverse |
No one on the platform has traded IKNA yet.
| $633M |
| — |
| ICPTIntercept Pharmaceuticals, Inc. | $19.00 | +0.21% | $795M | — |
| ICVXIcosavax, Inc. | $15.31 | -0.91% | $769M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at NaN× sales vs its 178.5× historical median P/S.
Fair value ≈ $0.00 · price $17.16 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$IMA $IKNA 176m market cap is just about the same as the 175m they closed with after the rm, so basically at “fair value”. should see a 10q in a few months with new numbers and determine their cash burn. Hopefully I will have sold this bioturd before then. There’s a large multi billion growing TAM for Alopecia Areata and Atopic dermatitis, but I’m mainly here for the hopeful pump job since most of these dilute and dump after the pump
View on StockTwits ↗$IMA $IKNA my largest position --> PIPE owners have incentive to push this to $350m mkt cap which is around $30 - $35 --> as I have been saying this is my low risk - just wait and let them push it up like $TECX
View on StockTwits ↗$IKNA should grind to $35 area as long as the market holds a bid
View on StockTwits ↗$IKNA trash ass stock
View on StockTwits ↗$IKNA what the hell happened today?
View on StockTwits ↗$IKNA merger plus rs plus name and ticker change monday, explosive cocktail!
View on StockTwits ↗$IKNA I think they launch this today before the split
View on StockTwits ↗Today's Top 5 Gainers Report: $LIDR (164%) $ARX (152%) $HCTI (127%) $IKNA (99%) $IXHL (68%) Live alerts from tradethehalt.com
View on StockTwits ↗$IKNA https://anachart.com/wp-content/uploads/ana_temp/1753452119_soc-img.jpg
View on StockTwits ↗Wedbush updates rating for Ikena Oncology ( $IKNA ) to Neutral, target set at 25 → 23.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.